Steroid hormone receptor signaling in tumorigenesis

Journal of Cellular Biochemistry

Volumn 96, Issue 3, 2005, Pages 490-505

  Singh, Rajesh R ^a   Kumar, Rakesh ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Coregulators; Estrogen receptors; Nongenomic; PELP1; Signaling; Steroid hormone receptors; Transcription

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR BETA; EXEMESTANE; FULVESTRANT; LETROZOLE; PROTEIN PELP1; REGULATOR PROTEIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STEROID HORMONE; STEROID RECEPTOR; STEROID RECEPTOR COACTIVATOR 1; TAMOXIFEN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

CARCINOGENESIS; DRUG MECHANISM; DRUG RECEPTOR BINDING; GENETIC TRANSCRIPTION; HUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN STABILITY; RECEPTOR INTRINSIC ACTIVITY; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; HISTONE ACETYLTRANSFERASES; HUMANS; NEOPLASMS; RECEPTORS, ESTROGEN; RECEPTORS, STEROID; SIGNAL TRANSDUCTION; STEROIDS; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS;

EID: 25844509783     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.20566     Document Type: Review

References (136)

1. Abba MC, Hu Y, Sun H, Drake JA, Gaddis S, Baggerly K, Sahin A, Aldaz CM. 2005. Gene expression signature of estrogen receptor α status in breast cancer. BMC Genomics 6:37-44.
2. Acconcia F, Ascenzi P, Bocedi A, Spisni E, Tomasi V, Trentalance A, Visca P, Marino M. 2005. Palmitolyation dependent estrogen receptor alpha membrane localization: Regulation by 17β-estradiol. Mol Biol Cell 16:231-237.
3. Ali S, Metzger D, Bornert JM, Chambon P. 1993. Phosphorylation of human estrogen receptor. Identification of a phosphorylation site recquired for transactivation. EMBO J 12:1153-1160.
4. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS. 1997. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277(5328):965-968.
5. Aronica SM, Kraus WL, Katzenellenbogen BS. 1994. Estrogen action via the cAMP-signaling pathway: Stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc Natl Acad Sci USA 91(18): 8517-8521.
6. Balasenthil S, Vadlamudi RK. 2003. Functional Interactions between the Estrogen Receptor Coactivator PELP1/MNAR and Retinoblastoma Protein. J Biol Chem 278:22119-22127.
7. Bardin A, Hoffmann P, Boulle N, Katsaros D, Vignon F, Pujol P, Lazennec G. 2004. Involvement of estrogen receptor beta in ovarian carcinogenesis. Cancer Res 64(16):5861-5869.
8. Barletta F, Wong CW, McNally C, Komm BS, Katzenellenbogen B, Cheskis BJ. 2004. Characterization of the interactions of estrogen receptor and MNAR in the activation of cSrc. Mol Endocrinol 18:1096-1108.
9. Bautista S, Valles H, Walker RL, Anzick S, Zeillinger R, Meltzer P, Theillet C. 1998. In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. Clin Cancer Res 4:2925-2929.
10. Bjornstrom L, Sjoberg M. 2005. Mechanisms of estrogen receptor signaling: Convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 19(4): 833-842.
11. Bouras T, Southey MC, Venter DJ. 2001. Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu. Cancer Res 61:903-907.
12. Brandenberger AW, Tee MK, Jaffe RB. 1998. Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: Down-regulation of ER-beta in neoplastic tissues. J Clin Endocrinol Metab 83(3):1025-1028.
13. Bruch HR, Wolf L, Budde R, Romalo G, Schweikert HU. 1992. Androstenedione metabolism in cultured human osteoblast-like cells. J Clin Endocrinol Metab 75(1):101-105.
14. Castro-Rivera E, Samudio I, Safe S. 2001. Estrogen regulation of cyclin D1 gene expression in ZR-75 breast cancer cells involves multiple enhancer elements. J Biol Chem 276(33):30853-30861.
15. Chakravarthi D, LaMorte VJ, Nelson MC, Nakajima T, Schulman IG, Juguilon H, Montminy M, Evans RM. 1996. Role of CBP/p300 in nuclear receptor signaling. Nature 383:99-103.
16. Chen H, Lin RJ, Schiltz RL, Chakravarthi D, Nash A, Nagy L, Privalsky ML, Nakatani Y, Evans RM. 1997. Nuclear receptor coactivator ACTR is a novel histone acetyl transferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 90:569-580.
17. Chen D, Ma H, Hong H, Koh SS, Huang SM, Schurter BT, Aswad DW, Stallcup MR. 1999. Regulation of transcription by a protein methyltransferase. Science 284:2174-2177.
18. Chen D, Pace PE, Coombes RC, ALI S. 1999. Phosphorylation of human estrogen receptor alpha by PKA regulates dimerization. Mol Cell Biol 19:1002-1015.
19. Chen Z, Yuhanna IS, Galcheva-Gargova Z, Karas RH, Mendelsohn ME, Shaul PW. 1999. Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest 103(3): 401-406.
20. Cheskis BJ. 2004. Regulation of cell signalling cascades by steroid hormones. J Cell Biochem 93:20-27.
21. Chin-Yo L, Anders S, Vinsensius BV, Say Li K, Ai Li Yeo, Thomsen JS, Chan WC, Doray B, Bangarusamy DK, Ramasamy A, Vergara LA, Tang S, Chong A, Bajic VB, Miller LD, Gustafsson JA, Liu ET. 2004. Discovery of estrogen receptor a target genes and response elements in breast tumor cells. Genome Biol 5(R66):1-18.
22. Choi YB, Ko JK, Shin J. 2004. The Transcriptional Corepressor, PELP1, Recruits HDAC2 and Masks Histories Using Two Separate Domains. J Biol Chem 279: 50930-50941.
23. Cole MP, Jones CT, Todd ID. 1971. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer 25(2):270-275.
24. Coser KR, Chesnes J, Hur J, Ray S, Isselbacher KJ, Shioda T. 2003. Global analysis of ligand sensitivity of estrogen inducible and suppressible genes in MCF7/BUS breast cancer cells by DNA microarray. Proc Natl Acad Sci USA 100:13994-13999.
25. Cowley SM, Parker MG. 1999. A comparison of transcriptional activation by REα and REβ. J Steroid Biochem Mol Biol 69:165-175.
26. Cunliffe HE, Ringner M, Bilke S, Walker RL, Cheung JM, Chen Y, Meltzer PS. 2003. The gene expression response of breast cancer to growth regulators: Patterns and correlation with tumor expression profiles. Cancer Res 63:7158-7166.
27. Early Breast Cancer Trialists' Collaborative Group. 1998. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351:1451-1467.
28. Endoh H, Sasaki H, Maruyama K, Takeyama K, Waga I, Shimizu T, Kato S, Kawashima H. 1997. Rapid activation of MAP kinase by estrogen in the bone cell line. Biochem Biophys Res Commun 235(1):99-102.
29. Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G, Nordenskjold M, Gustafsson JA. 1997. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 12:4258-4265.
30. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. 1994. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86(7):527-537.
31. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N. 1998. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90(18):1371-1388.
32. Foley EF, Jazaeri AA, Shupnik MA, Jazaeri O, Rice LW. 2000. Selective loss of estrogen receptor beta in malignant human colon. Cancer Res 60(2):245-248.
33. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS. 2003. Profiling of estrogen up- and downregulated gene expressionin human breast cancer cells: Insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144:4562-4574.
34. Fu M, Wang C, Reutens AT, Ang J, Angeletti RH, Siconolfi-Baez L, Ogryzko V, Avantagiatti ML, Pestell RG. 2000. p300 and p300/camp-response element binding protein associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem 275:20853-20860.
35. Fu M, Wang C, Zhang X, Pestell RG. 2004. Acetylation of nuclear receptors in cellular growth and apoptosis. Biochem Pharmacol 68:1199-1208.
36. Fuqua SA, Wiltschke C, Zhang QX, Borg A, Castles CG, Friedrichs WE, Hopp T, Hilsenbeck S, Mohsin S, O'Connell P, Allred DC. 2000. A hypersensitive estrogen receptor alpha mutation in premalignant lesions. Cancer Res 60:4026-4029.
37. Gaughan L, Logan IR, Cook S, Neal DE, Robson CN. 2002. Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to acetylation status of the receptor. J Biol Chem 277:25904-25913.
38. Gottlicher M, Heck S, Herlich P. 1998. Transcriptional cross talk, the second mode of steroid hormone receptor action. J Mol Med 76:480-489.
39. Hall JM, McDonnell DP. 1999. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140(12):5566-5578.
40. Henderson BE, Ross RK, Pike MC, Casagrande JT. 1982. Endogenous hormones as a major factor in human cancer. Cancer Res 42:3232-3239.
41. Hong H, Kohli K, Trivedi A, Johnson DL, Stallcup MR. 1996. GRIP1 a novel mouse protein that acts as a transcriptional coactivator in yeast for the hoemonal binding domains of steroid receptors. Proc Natl Acad Sci USA 93:4948-4952.
42. Howell A, Osborne CK, Morris C, Wakeling AE. 2000. ICI 182,780 (Faslodex): Development of a novel, "pure" antiestrogen. Cancer 89(4):817-825.
43. Huang ZJ, Edery I, Robash M. 1993. PAS is a dimerization domain common to Drosophila period and several transcription factors. Nature 364:259-262.
44. Huang ZQ, Li J, Sachs LM, Cole PA, Wong J. 2003. A role for cofactor-cofactor and cofactor-histone interactions in targeting p300, SWI/SNF, and mediator for transcription. EMBO J 22:2146-2155.
45. Huggins C, Hodges CV. 2002. Studies on prostatic cancer: The effect of castration, of estrogen and of androgen injections on serum phosphatases in metastatic carcinoma of the prostrate. J Urology 168:9-12.
46. Improta-Brears T, Whorton AR, Codazzi F, York JD, Meyer T, McDonnell DP. 1999. Estrogen-induced activation of mitogen-activated protein kinase requires mobilization of intracellular calcium. Proc Natl Acad Sci USA 96(8): 4686-4691.
47. Inoue A, Yoshida N, Omoto Y, Oguchi S, Yamori T, Kiyama R, Hayashi S. 2002. Development of cDNA microarray for expression profiling of estrogen-responsive genes. J Mol Endocrinol 29:175-192.
48. Ito M, Roeder RG. 2001. The TRAP/SMCC/mediator complex and thyroid hormone receptor function. Trends Endocrinol Metab 12:127-134.
49. Jackson TA, Richer JK, Brain DL, Takimoto GS, Tung L, Horwitz KB. 1997. The partial agonist activity of antagonist occupied steroid receptors is controlled by a novel hinge domain coactivator L7/SPA and the corepressor N-CoR or SMRT. Mol Endcrinol 11:693-705.
50. Jensen EV, Jordan VC. 2003. The estrogen receptor: A model for molecular medicine. Clin Cancer Res 9:1980-1989.
51. Joel PB, Traish AM, Lannigan DA. 1988. Estradiol-induced phosphorylation of serine 118 in estrogen receptor is independent of p42/p44 mitogen-activated protein kinase. J Biol Chem 273:13317-13323.
52. Joel PB, Smith J, Sturgill TW, Fisher TL, Blenis J, Lannigan DA. 1998. pp90rsk1 regulates estrogen receptor mediated transcription through phosphorylation of serines 167. Mol Cell Biol 18:1978-1984.
53. Johnston SR. 1997. Acquired tamoxifen resistance in human breast cancer-potential mechanisms and clinical implications. Anticancer Drugs 8(10):911-930.
54. Johnston SR. 2005. Endocrinology and hormone therapy in breast cancer: Selective oestrogen receptor modulators and doenregulators for breast cancer-have they lost their way? Breast Cancer Res 7:119-130.
55. Kato S, Endho H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P. 1995. Activation of the estrogen receptor through phosphorylation by mitogens-activated protein kinase. Science 270:1491-1494.
56. Khan SA, Rogers MA, Khurana KK, Meguid MM, Numann PJ. 1998. Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst 90:37-42.
57. Koh SS, Chen D, Lee YH, Stallcup MR. 2001. Synergistic enhancement of nuclear receptor function by p160 coactivators with protein methyltransferase activities. J Biol Chem 276:1089-1098.
58. Kotaja N, Aittomaki S, Silvennoinen O, Palvimo JJ, Janne OA. 2000. ARIP3 and other PIAS proteins differ in their ability to modulate steroid receptor dependent transcriptional activation. Mol Endocrinol 14:1986-2000.
59. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. 1996. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93(12):5925-5930.
60. Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson JA. 1997. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138(3):863-870.
61. Lan L, Kuang S-Q, Yuan Y, Gonzalez SM, O'Malley BW, Xu J. 2003. Molecular structure and biological function of the cancer-amplified nuclear receptor coactivator SRC-3/ AIB1. J Steroid Biochem Mol Biol 83:3-14.
62. Landet V. 1997. Evolution of nuclear receptor superfamily: Early diversification from an ancesteral orphan receptor. J Mol Endocrinology 19:207-226.
63. Lanz RB, McEnna NJ, Onate SA, Albrecht U, Wong J, Tsai MJ, O'Malley BW. 1999. A steroid receptor coactivator, SRA, functions as RNA and is present in an SRC-1 complex. Cell 97:17-27.
64. Lazennec G, Bresson D, Lucas A, Chauveau C, Vignon F. 2001. ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology 142(9):4120-4130.
65. Le Goff P, Montono MM, Schodin DJ, Katzenelenbogen BS. 1994. Phosphorylation of human estrogen receptor. Identification of hormone regulated sites and examination of their influence on transcriptional activity. J Biol Chem 269:4458-4466.
66. Leo C, Chen DJ. 2000. The SRC family of nuclear receptor coactivators. Gene 245:1-11.
67. Lerner L, Jordan V. 1990. Development of antiestrogens and their use in breast cancer: Eighth Cain memorial award lecture. Cancer Res 50:4177-4189.
68. Levy DE, Darnell JE. 2002. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3:651-662.
69. Li J, O'Malley BW, Wong J. 2000. p300 requires its histone acetyl transferase activity and SRC-1 interaction domain to facilitate thyroid hormone receptor activation in chromatin. Mol Cell Biol 20:2031-2042.
70. Li P, Yu X, Ge K, Melamed J, Roeder RG, Wang Z. 2002. Heterogeneous expression and functions of androgen receptor co-factors in primary prostrate cancers. Am J Pathol 161:1467-1474.
71. Li L, Hanes MP, Bender JR. 2003a. Plasma membrane localization and function of the estrogen receptor alpha variant (ER46) in human endothelial cells. Proc Natl Acad Sci USA 100:4807-4812.
72. Li X, Wong J, Tsai SY, Tsai MJ, O'Malley BW. 2003b. Progesterone and glucocorticoid receptors recruit distinct paterns of local chromatin modifications. Mol Cell Biol 23:3763-3773.
73. List HJ, Lauritsen KJ, Reiter R, Powers C, Wellstein A, Reigel AT. 2001. Ribozyme targeting demonstrates that the nuclear receptor coactivator AIB1 is a rate-limiting factor of estrogen dependent growth of human MCF-7 breast cancer cells. J Biol Chem 276:23763-23768.
74. List HJ, Reiter R, Singh B, Wellstein A, Riegel AT. 2001. Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue. Breast Cancer Res Treat 68:21-28.
75. Losel R, Wehling M. 2003. Nongenomic actions of steroid hormones. Nat Rev in Mol Cell Biol 4:46-56.
76. Manavathi B, Nair SS, Wang R-A, Kumar R, Vadlamudi RK. 2005. PELP1 is essential in growth factor regulation of STAT3 activation. Cancer Res In press.
77. Marino M, Acconcia F, Bresciani F, Weisz A, Trentalance A. 2002. Distinct nongenomic signal transduction pathways controlled by 17beta-estradiol regulate DNA synthesis and cyclin D (1) gene transcription in HepG2 cells. Mol Biol Cell 13(10):3720-3729.
78. McGuire WL, Carbone PP, Vollmer EP. 1975. Estrogen receptor in human breast cancer. New York: Raven Press.
79. Michalides R, Griekspoor A, Balkenende A, Verwoerd D, Janssen L, Jalink K, Floore A, Velds A, van't Veer L, Neefjes J. 2004. Tamoxifen resistance of by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. Cancer Cell 5:597-605.
80. Migliaccio A, Di Domenico M, Castoria G, de Falco A, Bontempo P, Nola E, Auricchio F. 1996. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J 15(6):1292-1300.
81. Moilanen AM, Karvonen U, Poukka H, Yan W, Toppari J, Janne OA, Palvimo JJ. 1998. Identification of a novel RING finger protein as a coregulator in steroid receptor regulated gene transcription. Mol Cell Biol 18:5128-5139.
82. Mosselman S, Polman J, Dijkema R. 1996. ER beta: Identification and characterization of a novel human estrogen receptor. FEES Lett 392(1):49-53.
83. Naftolin F, Ryan KJ, Davies IJ, Reddy W, Flores F, Petro Z, Kuhn M, White RJ, Takaoka Y, Wolin L. 1975. The formation of estrogens by central neuroendocrine tissues. Recent Prog Horm Res 31:295-319.
84. Nair SS, Mishra SK, Yang Z, Balasenthil S, Kumar R, Vadlamudi RK. 2004. Potential role of a novel transcriptional coactivator PELP1 in histone H1 displacement in cancer cells. Cancer Res 64:6416-6423.
85. Nowaz Z, Lonard DM, Smith CL, Lev-Lehman E, Tsai SY, Tsai MJ, O'Malley BW. 1999. The Angelman syndrome associated protein, E6-AP, is a coactivator for the nuclear hormone receptor superfamily. Mol Cell Biol 19:1182-1189.
86. O'Lone R, Firth MC, Karlsson EK, Hansen U. 2004. Genomic targets of nuclear estrogen receptors. Mol Endocrinol 18:1859-1875.
87. Ogawa S, Inoue S, Watanabe T, Orimo A, Hosoi T, Ouchi Y, Muramatsu M. 1998. Molecular cloning and characterization of human estrogen receptor betacx: A potential inhibitor of estrogen action in human. Nucleic Acids Res 26(15):3505-3512.
88. Ogawa S, Inoue S, Watanabe T, Hiroi H, Orimo A, Hosoi T, Ouchi Y, Muramatsu M. 2005. The complete primary structure of human estrogen receptor beta (hER beta) and its heterodimerization with ER alpha in vivo and in vitro. Biochem Biophys Res Commun 243(1):122-126.
89. Omoto Y, Eguchi H, Yamamoto-Yamaguchi Y, Hayashi S. 2003. Estrogen receptor (ER) beta1 and ERbetacx/beta2 inhibit ERalpha function differently in breast cancer cell line MCF7. Oncogene 22(32):5011-5020.
90. Onate SA, Tsai SY, Tsai MJ, O'Malley BW. 1995. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270:1354-1357.
91. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R. 2003. Role of estrogen receptor coactivator AIB1 (SRC-3) and HER2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95:353-361.
92. Pace P, Taylor J, Suntharalingam S, Coombes RC, Ali S. 1997. Human estrogen receptor beta binds DNA in a manner similar to and dimerizes with estrogen receptor alpha. J Biol Chem 272(41):25832-25838.
93. Paech K, Webb P, Kuiper G, Nilson S, Gustafsson JA, Kushner PJ, Scalan TS. 1997. Differential ligand activation of estrogen receptors REα and REβ at AP-1 site. Science 277:1508-1510.
94. Pappas TC, Gametchu B, Watson CS. 1995. Membrane estrogen receptors identified by multiple antibody labeling and impeded ligand binding. FASEB J 9:404-410.
95. Parker MG. 1993. Action of 'pure' antiestrogen in inhibiting estrogen receptor action. Breast Cancer Res Treat 26: 131-137.
96. Peng B, Lu B, Leygue E, Murphy LC. 2003. Putative functional characteristics of human estrogen receptor-beta isoforms. Mol Endocrinol 30(1):13-29.
97. Pettersson K, Delaunay F, Gustafsson JA. 2000. Estrogen receptor beta acts as a dominant regulator of estrogen signaling. Oncogene 19(43):4970-4978.
98. Pike MC, Krailo MO, Henderson BE, Casagrande JT, Hoel DG. 1983. Hormonal risk factors, breast tissue age, and the age incidence of breast cancer. Nature 303:767-770.
99. Planas-Silva MD, Shang Y, Donaher JL, Brown M, Weinberg RA. 2001. AIB1 enhances estrogen-dependent induction of cyclin Dl expression. Cancer Res 61:3858-3862.
100. Pujol P, Rey JM, Nirde P, Roger P, Gastaldi M, Laffargue F, Rochefort H, Maudelonde T. 1998. Differential expression of estrogen receptor-alpha and -beta messenger RNAs as a potential marker of ovarian carcinogenesis. Cancer Res 58(23):5367-5373.
101. Razandi M, Pedram A, Park ST, Levin ER. 2005. Proximal events in signaling by plasma membrane estrogen receptors. J Biol Chem 278(4):2701-2712.
102. Rogatsky I, Trowbridge JM, Garabedian MJ. 1999. Potentiation of human estrogen receptor alpha transcriptional activation through phosphorylation of serines 104 and 106 by cyclin A-CDK2 complex. J Biol Chem 274:22296-22302.
103. Rutherford T, Brown WD, Sapi E, Aschkenazi S, Munoz A, Mor G. 2000. Absence of estrogen receptor-beta expression in metastatic ovarian cancer. Obstet Gynecol 96(3): 417-421.
104. Sabbah M, Courilleau D, Mester J, Redeuilh G. 1999. Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element. Proc Natl Acad Sci USA 96(20):1217-112122.
105. Santen RJ, Harvey HA. 1999. Use of aromatase inhibitors in breast carcinoma. Endocr Relat Cancer 6(1):75-92.
106. Santen RJ, Worgul TJ, Lipton A, Harvey H, Boucher A, Samojlik E, Wells SA. 1982. Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma. Ann Intern Med 96(1):94-101.
107. Sasano H, Murakami H, Shizawa S, Satomi S, Nagura H, Harada N. 1999. Aromatase and sex steroid receptors in human vena cava. Endocr J 46(2):233-242.
108. Savkur RS, Burris TP. 2004. The coactivator LXXLL nuclear receptor recognition motif. J Peptide Res 63: 207-212.
109. Shaffer PL, Jivan A, Dollins DE, Claesseus F, Gewirth DT. 2004. Structural basis of androgen receptor binding to selective androgen response elements. PNAS 101:4758-4763.
110. Shang Y, Hu X, Di Renzo J, Lazar MA, Brown M. 2000. Cofactor dynamics and sufficiency in estrogen receptor regulated transcription. Cell 103:843-852.
111. Sharma D, Fondell JD. 2002. Ordered recruitment of histone acetyltransferases and the TRAP/mediator complex to thyroid hormone responsive promoters in vivo. Proc Natl Acad Sci USA 99:7934-7939.
112. Shoker BS, Jarvis C, Clark RB. 1999. Estrogen receptor-positive proliferating cells in the normal and precancerous breast. Am J Pathol 155:184-185.
113. Simpson ER, Dowsett M. 2002. Aromatase and its inhibitors: Significance for breast cancer therapy. Recent Prog Horm Res 57:317-338.
114. Simpson ER, Zhao Y, Agarwal VR, Michael MD, Bulun SE, Hinshelwood MM, Graham-Lorence S, Sun T, Fisher CR, Qin K, Mendelson CR. 1997. Aromatase expression in health and disease. Recent Prog Horm Res 52:185-213.
115. Sinn E, Muller W, Pattengale P, Tepler I, Wallace R, Leder P. 1987. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: Synergistic action of oncogenes in vivo. Cell 49:465-475.
116. Sivaraman L, Nawaz Z, Medina D, Conneely OM, O'Malley BW. 2000. The dual function steroid receptor coctivator/ubiquitin ligase, E6-AP is ovexpressed in mouse mammary tumorigenesis. Breast Cancer Res Treat 62:185-195.
117. Strom A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA. 2004. Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci USA 101(6): 1566-1571.
118. Tan J, Hall SH, Hamil KG, Grossman G, Petrusz P, Liao J, Shuai K, French FH. 2000. Protein inhibitor of activated STAT1 is a nuclear receptor coregulator expressed in human testis. Mol Endocrinol 14:14-26.
119. Tenenbaum DM, Wang Y, Williams SP, Sigler PB. 1998. Crystallographic comparison of the estrogen and progesterone receptors' ligand binding domains. PNAS 95:5998-6003.
120. Torchia J, Rose DW, Inostroza J, Kamei Y, Westin S, Glass CK, Roesnfeld GM. 1997. The transcriptional coactivator p/CIP binds CBP and mediated nuclear receptor function. Nature 387:677-684.
121. Tremblay GB, Tremblay A, Copeland NG, Gilbert DJ, Jenkins NA, Labrie F, Giguere V. 1997. Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta. Mol Endocrinol 3:353-365.
122. Umesono K, Evans RM. 1989. Determinants of target gene specificity for steroid/thyroid hormone receptors. Cell 57:1139-1146.
123. Vadlamudi RK, Wang R-A, Mazumdar A, Kim Y-S, Shin J, Sahin A, Kumar RK. 2001. Molecular cloning and molecular characterization of PELP1, a novel coregulator of estrogen receptor α. J Biol Chem 276:38272-39279.
124. Vadlamudi RK, Balasenthil S, Broaddus RR, Gustafsson JA, Kumar R. 2004. Deregulation of estrogen receptor coactivator proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor in human endometrial tumors. J Clin Endocrinol Metab 89:6130-6138.
125. Voegel JJ, Heine MJ, Zechel C, Chambon P, Gronemeyer H. 1996. TIF2 a 160 kilodalton transcriptional mediator for the ligand dependent activation function AF-2 of nuclear receptors. EMBO J 15:3667-3675.
126. Voegel JJ, Hiene MJ, Tini M, Vivat V, Chambon P, Gronemeyer H. 1998. The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and -independent pathways. EMBO J 17:507-519.
127. Wang C, Fu M, Angelletti RH, Siconolfi-Baez L, Reutens AT, Albanese C, Lisanti MP, Katzenellenbogen BS, Kato S, Hop T, Fuqua SA, Lopez GN, Kushner PJ, Pestell RG. 2001. Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity. J Biol Chem 276(21):18375-18383.
128. Wang RA, Mazumdar A, Vadlamudi RK, Kumar R. 2002. P21-activated kinase-1 phosphorylates and transactivates estrogen receptor-a and promotes hyperplasia in mammary epithelium. EMBO J 21:5437-5447.
129. Webb P, Valentine C, Nguyen P, Price RH Jr, Marimuthu A, West BL, Baxter JD, Kushner PJ. 2003. ERbeta Binds N-CoR in the Presence of Estrogens via an LXXLL-like Motif in the N-CoR C-terminus. Nucl Recept 281:1-4.
130. Weihua Z, Makela S, Andersson LC, Salmi S, Saji S, Webster JI, Jensen EV, Nilsson S, Warner M, Gustafsson JA. 2001. A role for estrogen receptor beta in the regulation of growth of the ventral prostate. Proc Natl Acad Sci USA 98(11):6330-6335.
131. Wies KE, Ekena K, Thomas JA, Lazennec G, Katzenellenbogen BS. 1996. Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. Mol Endocrinol 10:1388-1398.
132. Witte D, Chirala M, Younes A, Li Y, Younes M. 2001. Estrogen receptor beta is expressed in human colorectal adenocarcinoma. Hum Pathol 32(9):940-944.
133. Wong CW, McNally C, Nickbarg E, Komm BS, Cheskis BJ. 2002. Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc Natl Acad Sci USA 99:14783-14788.
134. Wurtz JM, Bourguet W, Renaud JP, Vivat V, Chambon P, Moras D, Gronemeyer H. 1996. A canonical structure for the ligand-binding domain of nuclear receptors. Nat Struct Biol 3:87-94.
135. Yeh C, Chang C. 1996. Cloning and characterization of a specific coactivator ARA70, for androgen receptor I human prostate cells. Proc Natl Acad Sci USA 93:5517-5521.
136. Zhang QX, Borg A, Wolf DM, Oesterreich S, Fuqua AS. 1997. An estrogen receptor mutant with strong hormone independent activity from a metastatic breast cancer. Cancer Res 57:1244-1249.